DUBLIN–(BUSINESS WIRE)–The “Project Management for Pharma Professionals Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarketsDUBLIN–(BUSINESS WIRE)–The “Project Management for Pharma Professionals Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarkets

2 Day Pharma Professionals Project Management Training Course (Online Event: Mar 9th – Mar 10th, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Project Management for Pharma Professionals Training Course (Mar 9th – Mar 10th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This interactive two-day course has been designed to provide you with a thorough understanding of both technical and interpersonal project management skills.

Drug and device development is a complex process which needs effective project management. With ever-increasing pressures in the industry, the use of project management can provide essential tools and techniques and be a key factor in the successful completion of bringing a drug or medical device to market – as demonstrated by the FDA critical path initiative.

Interactive exercises are used to aid the learner in the application of project management concepts and principles so they can easily use the tools to improve the success of existing or future pharmaceutical projects.

The programme will include a number of sessions where you will be able to apply some of the techniques to a simulated pharmaceutical case study as well as your own projects. You are therefore encouraged to bring a real project you are currently involved in or will be working on to which you can apply some of the concepts and techniques. There is no need to disclose any confidential information about your project.

Benefits of attending:

  • Acquire an in-depth understanding of technical project management methodologies and techniques to apply to pharma/bio projects, including agile project management
  • Learn how to incorporate these project management processes into everyday working practices and your current projects
  • Understand how to blend together both the technical aspects of project management and the essential interpersonal skills
  • Discover how to build core competencies to become an even more effective project manager
  • Discuss how to get the best results in a project team environment

Aims and objectives

The objective of this course is to ensure you gain a comprehensive understanding of the tools and techniques of project management and discover how they can be applied straight away to your own pharma/bio or medical device projects.

The programme has been specially designed to ensure that you:

  • Understand technical project management tools and techniques and can apply these to your work
  • Examine the competencies appropriate for an effective project manager
  • Identify the project critical path and use this information to assist in planning decisions
  • Gain a better understanding of the essential personal skills which are necessary to achieve project objectives

Who Should Attend:

  • This course has been specifically designed to address the needs of pharma/bio professionals as well as those in the medical device and animal health industries.
  • The programme will benefit both newly appointed and established project team leaders/managers wishing to refresh or update their skills.

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

What is a Project/Project Management in the pharma/bio industry?

  • Defining the key characteristics of project management and their importance to the bio/pharma industry
  • Using a project management process for improving the success of your own projects
  • Sharing experiences and lessons learned from previous bio/pharma projects

Setting clear project objectives and defining the scope of pharma/bio projects

  • Aligning the project objectives with the strategic and financial business objectives
  • Defining the result, the cost and the time
  • Understanding the importance of having an overall strategy for your projects

Detailed project planning of pharma/bio projects

  • Identifying the key project activities using a Work Breakdown Structure (WBS)
  • Allocate responsibilities using the responsibility matrix
  • Planning a realistic schedule using Gantt analysis and setting clear milestones
  • Budget planning, Communication plan, Quality plan
  • Implementing risk management and contingency planning for your project
  • Experiences of project management software and tracking systems

Project implementation and control for your projects

  • Identifying the possible causes of problems in pharmaceutical/bio projects
  • Effective communication and how to manage stakeholders
  • Overcoming enablers and constraints of your projects
  • Implementing project control and reporting systems
  • Monitoring project activities and performance

Day 2

Project review and closure

  • Close the project
  • Identifying the critical success factors and learning from mistakes

Pharma/bio leadership skills

  • Defining the role and skills of effective pharma project leaders
  • Improving your interpersonal skills as a leader

Motivate to achieve project milestones

  • Understand how to motivate different people and what motivates your project team
  • Completion of a self-evaluation questionnaire

Building pharma/bio project teams

  • How to modify your leadership style to get the best results in a project team environment
  • Building a high performance team

Project communication and cross-cultural communication skills

  • Effective communication and how to gain project buy-in
  • Preventing and overcoming misunderstandings and dealing with conflict
  • Communicating effectively with the project stakeholders including cross culturally

Project time management

Speakers:

Laura Brown

Pharmaceutical QA and Training Consultant

University of Cardiff

Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years’ experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International.

She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including “The Planning of International Drug Development”, in the Clinical Research Manual, Euromed and the “Impact of Brexit”, RQA Journal 2017.

For more information about this training visit https://www.researchandmarkets.com/r/q85det

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny

The post Shocking OpenVPP Partnership Claim Draws Urgent Scrutiny appeared on BitcoinEthereumNews.com. The cryptocurrency world is buzzing with a recent controversy surrounding a bold OpenVPP partnership claim. This week, OpenVPP (OVPP) announced what it presented as a significant collaboration with the U.S. government in the innovative field of energy tokenization. However, this claim quickly drew the sharp eye of on-chain analyst ZachXBT, who highlighted a swift and official rebuttal that has sent ripples through the digital asset community. What Sparked the OpenVPP Partnership Claim Controversy? The core of the issue revolves around OpenVPP’s assertion of a U.S. government partnership. This kind of collaboration would typically be a monumental endorsement for any private cryptocurrency project, especially given the current regulatory climate. Such a partnership could signify a new era of mainstream adoption and legitimacy for energy tokenization initiatives. OpenVPP initially claimed cooperation with the U.S. government. This alleged partnership was said to be in the domain of energy tokenization. The announcement generated considerable interest and discussion online. ZachXBT, known for his diligent on-chain investigations, was quick to flag the development. He brought attention to the fact that U.S. Securities and Exchange Commission (SEC) Commissioner Hester Peirce had directly addressed the OpenVPP partnership claim. Her response, delivered within hours, was unequivocal and starkly contradicted OpenVPP’s narrative. How Did Regulatory Authorities Respond to the OpenVPP Partnership Claim? Commissioner Hester Peirce’s statement was a crucial turning point in this unfolding story. She clearly stated that the SEC, as an agency, does not engage in partnerships with private cryptocurrency projects. This response effectively dismantled the credibility of OpenVPP’s initial announcement regarding their supposed government collaboration. Peirce’s swift clarification underscores a fundamental principle of regulatory bodies: maintaining impartiality and avoiding endorsements of private entities. Her statement serves as a vital reminder to the crypto community about the official stance of government agencies concerning private ventures. Moreover, ZachXBT’s analysis…
Share
BitcoinEthereumNews2025/09/18 02:13
5 Top Crypto to Invest In 2025: From BNB to BlockchainFX, Who Holds the Crown?

5 Top Crypto to Invest In 2025: From BNB to BlockchainFX, Who Holds the Crown?

Detail: https://coincu.com/pr/5-top-crypto-to-invest-in-2025-from-bnb-to-blockchainfx-who-holds-the-crown/
Share
Coinstats2025/09/25 05:30
Will XRP Price Increase In September 2025?

Will XRP Price Increase In September 2025?

Ripple XRP is a cryptocurrency that primarily focuses on building a decentralised payments network to facilitate low-cost and cross-border transactions. It’s a native digital currency of the Ripple network, which works as a blockchain called the XRP Ledger (XRPL). It utilised a shared, distributed ledger to track account balances and transactions. What Do XRP Charts Reveal? […]
Share
Tronweekly2025/09/18 00:00